SilkTech announces IND clearance from FDA for the SDP-4 eye drop and initiates a Phase 2B clinical trial for patients with Dry Eye Disease.

SilkTech Biopharmaceutical’s Investigational New Drug (IND) submission has received clearance from the FDA and the company has initiated a Phase 2B clinical trial (SDP-4-CS201) to evaluate the ocular safety and efficacy of SDP-4 ophthalmic solution in subjects with moderate to severe Dry Eye Disease.  Press Release